Abstract PS4-03: An automated DNA methylation assay for monitoring treatment response in patients with metastatic breast cancer

Abstract

BACKGROUND: Previously, we demonstrated the clinical validity of cMethDNA, a circulating methylated tumor DNA (ctDNA) assay, in serum samples from TBCRC 005 (J Clin Oncol, 2017; 35:751-758) to predict progression free- and overall-survival, and to monitor therapeutic response in patients with stage IV breast cancer. Here, Johns Hopkins (JH) and Cepheid partnered to develop an automated GeneXpert (GX) cartridge-based system to provide quantitative measures of DNA methylation within 5 hours.METHODS: With a goal of discriminating stage IV breast cancer from healthy and benign breast disease with high sensitivity and specificity, we evaluated breast cancer-specific DNA methylation markers (selected through comprehensive methylome analysis) in STRECK tube plasma of 46 patients with metastatic breast cancer enrolled in Individualized Molecular Analyses Guide Efforts in Breast Cancer (IMAGE II trial), 17 benign breast disease and 9 healthy normal controls (J0888 repository). Blood from IMAGE II participants was collected upon disease progression. A newly designed GX Breast Cancer Monitoring Assay for research use only (RUO*) first converted unmethylated CpG sites in ctDNA from 1 ml plasma with bisulfite. The sample was then split into two methylation detection cartridges, which quantitated DNA methylation of 9 markers along with an ACTB reference. Cumulative methylation (CM) of the 9-gene panel was calculated using a novel algorithm. Performance was assessed based on Receiver Operating Characteristic (ROC) curves and Mann-Whitney analyses.RESULTS: The GX Breast Cancer Monitoring Assay (RUO)* showed that the 9-gene panel was significantly more methylated in cancer compared to normal/benign plasma samples (median for cancer: 428.0 CM units versus for benign: 0.0 CM units; P< 0.0001), and revealed a sensitivity of 85% and specificity of 92%, using a cumulative methylation threshold of 35.5 units based on ROC area under the curve (AUC) = 0.909 (95% CI 0.836 – 0.982, P<0.0001). We will present comparisons of the GX results to cMethDNA, the gold standard assay, which reported 85-90% sensitivity at 90% specificity.CONCLUSIONS: We identified a panel of methylated DNA markers that discriminates stage IV breast from benign breast disease and healthy normal subjects using ctDNA. Our automated cartridge-based assay prototype demonstrates high sensitivity and specificity for detecting invasive breast cancer. Its ability to assess changes in DNA methylation will be tested next with clinical trial samples collected longitudinally during treatment. This assay has potential clinical utility in monitoring therapeutic response and predicting disease recurrence.* For Research Use Only. Not for use in diagnostic procedures. Not reviewed by any regulatory body. Citation Format: Mary Jo Fackler, Suzana Tulac, Neesha Venkatesan, Adam J. Aslam, Leslie M. Cope, Jennifer Lehman, Rita Denbow, Jeffrey Reynolds, Morgan Buckley, Bradley M. Downs, Kala Visvanathan, Christopher B. Umbricht, Antonio C. Wolff, Vered Stearns, Edwin W. Lai, Saraswati Sukumar. An automated DNA methylation assay for monitoring treatment response in patients with metastatic breast cancer [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PS4-03.

Circulating Biomarkers in Breast Cancer

“…138 , 139 The same authors have recently developed a 9-gene methylation panel that utilizes automated cartridge-based technology, the GX Breast Cancer Monitoring Assay, which preliminarily demonstrates a sensitivity of 85% and specificity of 92%. 140 Additionally, Panagopoulou et al established a ccfDNA methylation panel of 5 genes, and methylation of 3 or more and 4 or more genes correlated to OS and no pharmacotherapy response, respectively. Using machine-learning and statistical analysis, they developed models for prediction of treatment response to chemotherapy and for OS in metastatic disease that used ccfDNA levels and ccfDNA methylation as parameters.…”